newsfilter
← Latest News
GlobeNewswire·

Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

CTA Approval from Germany's Federal Institute for Drugs and Medical Devices (BfArM), accompanied by a positive opinion from the Ethics Committee of the North Rhine Medical Association, clears Silexion to initiate